You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
|
|---|---|
| Published in |
Annals of Clinical Microbiology and Antimicrobials, June 2015
|
| DOI | 10.1186/s12941-015-0090-4 |
| Pubmed ID | |
| Authors |
Kevin Kim, Leeor Zilbermintz, Mikhail Martchenko |
| Abstract |
The high cost and prolonged timeline of new drug discovery and development are major roadblocks to creating therapies for infectious diseases. Candida albicans is an opportunistic fungal pathogen that is the most common cause of fatal fungal infections in humans and costs $2-4 billion dollars to treat in the US alone. To accelerate drug discovery, we screened a library of 1581 existing FDA approved drugs, as well as drugs approved abroad, for inhibitors of C. albicans. The screen was done on YPD yeast growth media as well as on the serum plate assay developed in this study. We discovered that fifteen drugs, all which were originally approved for treating various infectious and non-infectious diseases, were able to kill Candida albicans. Additionally, one of those drugs, Octodrine, displays wide-spectrum anti-microbial activity. Compared to other selected anti-Candida drugs, Octodrine was shown to be one of the most effective drugs in killing serum-grown Candida albicans without significantly affecting the survival of host macrophages and skin cells. This approach is useful for the discovery of economically viable new therapies against infectious diseases. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| France | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 2 | 50% |
| Scientists | 1 | 25% |
| Members of the public | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 3% |
| Unknown | 65 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 19% |
| Student > Bachelor | 12 | 18% |
| Researcher | 9 | 13% |
| Student > Master | 5 | 7% |
| Student > Postgraduate | 4 | 6% |
| Other | 13 | 19% |
| Unknown | 11 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 11 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 13% |
| Immunology and Microbiology | 8 | 12% |
| Biochemistry, Genetics and Molecular Biology | 7 | 10% |
| Medicine and Dentistry | 6 | 9% |
| Other | 11 | 16% |
| Unknown | 15 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2018.
All research outputs
#6,148,629
of 22,811,321 outputs
Outputs from Annals of Clinical Microbiology and Antimicrobials
#114
of 608 outputs
Outputs of similar age
#72,070
of 266,419 outputs
Outputs of similar age from Annals of Clinical Microbiology and Antimicrobials
#1
of 10 outputs
Altmetric has tracked 22,811,321 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 608 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,419 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them